PBS FRONTLINE: Hunting the Nightmare Bacteria

Dear All: 

Frontline will today broadcast an updated version of the excellent Hunting the Nightmare Bacteria show that first broadcast in 2013. Here’s the link to the announcement and here is the short description of this 1-h program:

“Described by the Centers for Disease Control and Prevention as “nightmare bacteria,” there are now predictions that drug-resistant superbugs will kill more people than cancer by 2050. From a young girl thrust onto life support in Arizona to an uncontrollable outbreak at one of the nation’s most prestigious hospitals, this updated version of our 2013 documentary explores the rise of the superbug threat, and whether the age of antibiotics may be coming to an end.”

For those of you who miss the broadcast or who do not have a local PBS station, the updated program will be available beginning tomorrow for streaming at http://www.pbs.org/wgbh/frontline/.

It’s so very helpful to have this story told and retold … it’s a hard idea to convey and I’m always grateful to journalists who work to find a way to communicate the core concepts.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top